Administration of conventional tablets of Propranolol has been reported to exhibit fluctuations in the plasma drug levels, resulting either in manifestation of side effects such as diarrhea, ischemic colitis and mesenteric arterial thrombosis or reduction in drug concentration at the receptor site. Transdermal drug delivery (TDD) method has been selected as it provides controlled release of the drug, and produces a steady blood-level profile, leading to reduced systemic side effects and, sometimes, improved efficacy over other dosage forms. In the present work, efforts have been made to prepare transdermal drug delivery system of Propranolol using various blends of polymers such as Eudragit RS 100, Hydroxy propyl methyl cellulose K100M and Poly vinyl pyrrolidone using propylene glycol as a permeation enhancer. The prepared patches were evaluated for various physicochemical properties and in-vitro drug release studies. The drug release data was fitted to statistical approach such as Zero order kinetics, Higuchi's and Peppa's plot. The optimized formulation from the in-vitro drug release study is used to carry out in-vitro skin permeation study using porcine ear skin, snake shed skin and rat skin. The in-vivo evaluation of formulation F 7 (1.5 % Eudragit RS 100, 1.5 % HPMC K100M) shown better correlation with the in-vitro drug release which confirms the achievement of targets of the present study such as controlled prolonged zero order release, reduced frequency of administration, greater therapeutic effect, overcome the side effects, simplify the treatment regimen and thus may improve patient compliance.

No abstract

No abstract

and 39.80 % were Female. 51.45 % of patients were prescribed with pantoprazole, 35.92 % of patients were prescribed with ranitidine, 3.88% of patients were prescribed with esomeprazole, 2.91 % of patients were prescribed with omeprazole, 2.91 % of patients were prescribed with rabeprazole, 0.97 % of patients were prescribed with ranitidine and pantoprazole, 0.97 % of patients were prescribed with ranitidine and rabeprazole and 0.97 % of patients were prescribed with pantoprazole and rabeprazole. 66.99 % of patients got headache, 35.92 % Diarrhea, 29.12 % Dizziness, 1.94 % vomiting and 0.97 % Abdominal pain and constipation. The overall analysis of total prescription (103) shows that 47.57% having drug interactions and 52.42 % having no drug interaction. ConClusions: The study revealed that the utilization of antiulcer drugs were rational and there was no serious adverse drug reactions and drug related problems in the prescription.